The American Journal of Managed Care12 小时
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem ...
FDA 授予 SER-155 突破性疗法认定
FDA已授予 SER-155 突破性疗法认定，用于减少接受异基因造血干细胞移植 (allo-HSCT) 治疗血液系统恶性肿瘤的成年人的血流感染 (BSI)。 美国食品药品监督管理局 (FDA) 已授予 SER-155 ...
Study finds outcomes after stem cell transplant in elderly patients with AML have improved ...
A ccording to a study published in Clinical Cancer Research, among patients over 65 who received an allogeneic hematopoietic ...
Too Old to Operate14 天
Renal-Limited TMA After Allo-HSCT With Membranous Nephropathy
The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and membranous nephropathy after allogeneic hematopoietic stem cell transplantation ...
The American Journal of Managed Care14 天
Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...
来自MSN2 个月
Benefits of Transplant for Pediatric Sickle Cell Disease Add Up a Decade Later
SAN DIEGO -- Kids with sickle cell disease who underwent allogeneic stem cell transplantation (allo-SCT) had fewer serious disease complications along with better quality-of-life and cognitive ...
Targeted Oncology6 天
Orca-T Shows Survival Benefit Over Cyclophosphamide in Transplant Study
A retrospective analysis showed improved overall survival (OS) with Orca-T compared with post-transplant cyclophosphamide in ...
Too Old to Operate14 天
Diagnosing and Treating CNS cGVHD With Rituximab in Refractory Cases
The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in the January 2025 issue of Hematology by Yokoyama et al. Chronic ...
Yahoo Finance22 天
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next ...
(Nasdaq: ALLO), a clinical-stage biotechnology company ... which leverages the clinically validated Dagger ® technology to drive CAR T cell expansion and prevent rejection, includes two distinct ...